# **Immunomodulation by mercuric chloride** *in vitro***: application of different cell activation pathways**

N. Y. A. Hemdan,\*†‡

I. Lehmann, † G. Wichmann, † J. Lehmann, § F. Emmrich\* and U. Sack\*

*\*Institute of Clinical Immunology and Transfusion Medicine (IKIT), University of Leipzig, Germany, † Department of Environmental Immunology (UFZ), Centre for Environmental Research Leipzig-Halle, Germany, ‡ Department of Zoology, Faculty of Science, University of Alexandria, Egypt, and § Fraunhofer Institute for Cell Therapy and Immunology, Biocity, Leipzig, Germany*

Accepted for publication 5 January 2007 Correspondence: Nasr Y. A. Hemdan, Max-Bürger-Forschungszentrum, Institut für Klinische Immunologie und Transfusionsmedizin, Johannisallee 30, D-04103 Leipzig, Germany. E-mail: hemdan.[nasr@medizin.uni-leipzig.de](mailto:nasr@medizin.uni-leipzig.de)

#### **Summary**

**Evidence is emerging that exposure to mercury (Hg) may elicit many pathological manifestations, including immunomodulation. We tested whether changing cellular activation pathways may affect the immunomodulation by Hg. Human cell cultures were set up where isolated peripheral blood mononuclear cells, activated by monoclonal antibodies (MoAb: anti-CD3/-CD28/- CD40) or heat-killed** *Salmonella enterica* **serovar Enteritidis (hk-***S***E), exposed** to mercuric chloride (HgCl<sub>2</sub>) for 24 h. Cell vitality was assessed by MTT assay, **and modulation of cytokine profiles were monitored by enzyme-linked immunosorbent assay (ELISA), intracellular cytokine staining and reverse transcription–polymerase chain reaction (RT–PCR). Results show that Hg doses above 15 ng/ml significantly reduced cell vitality (***P* **< 0·05). Lower doses elicited distinct effects on T helper 1 (Th1) and Th2 cytokine expression depending on cellular activation pathways. In MoAb-stimulated cells, interferon (IFN)-**g**, tumour necrosis factor (TNF)-**a **and interleukin (IL)-6 pro**duction was reduced. Doses up to 0.150 and 0.5 µg/ml increased IL-10 and **IL-4 production, respectively, resulting in significantly reduced Th1/Th2 ratios. Stimulation by hk-***S***E, however, elevated Th1/Th2 ratios due to induction of IFN-**g *versus* **IL-10 production. Taken together, we conclude that lowlevel exposure to Hg, in the absence of inflammation, polarizes the immune response toward Th2, but not in the case of Th1-polarized responses elicited by** *Salmonella* **antigens that can be promoted instead. This demonstrates differential** *in vitro* **effects of Hg on the Th1/Th2 balance produced by different stimuli, which may have important experimental and scientific implications.**

**Keywords:** cellular activation, helper T cells, immunotoxicity, inflammation, mercuric chloride

#### **Introduction**

Anthropogenic use has led to global dispersion of heavy metals such as mercury (Hg) into the environment. Mercury exists in three forms: elemental Hg, inorganic and organic forms, each of which has unique characteristics for the target organ specificity [1]. Potential sources of human exposure to Hg include inhalation of Hg vapours, ingestion of contaminated water and foodstuffs, chloro-alkali plants, gold mining, the production of lamps and batteries and through medical treatments and dental amalgam fillings that contain about 50% Hg by weight [2] and is assumed to be the important source of inorganic Hg exposure in the general population [3]. Dietary intake of fish and other seafood products is

the sole source of non-occupational exposure to the highly absorbable methylmercury form [2,4].

Many pathological manifestations caused by exposure to heavy metals have been reported. In general, substantial evidence exists to support the hypothesis that mammalian immunocompetent cellular components are sensitive to modulation by metal contaminants, including different forms of Hg that show diverse effects [5,6]. Exposure to Hg vapours and to organic Hg compounds affects specifically the central nervous system (CNS), while the kidney is the target organ for inorganic Hg. Implication of Hg in induction or exacerbation of diseases included allergic manifestations, neurodegenerative and autoimmune disorders in genetically susceptible animals as well as humans [2,4,6–10].

Together with other findings, results regarding low-level doses of Hg emerged from two large studies [4] have led many regulatory agencies to revise their tolerable limits. Thus, in 1997, the US Environmental Protection Agency (EPA) has lowered the safety level for Hg exposure from 0·5 mg Hg/kg body weight/day, the threshold established by the World Health Organization (WHO) in 1978 [11], to  $0.1 \,\mu g$  Hg/kg body weight/day, which is equivalent to blood Hg levels of  $4.0 - 5.0 \,\text{µg/l}$  [2,12,13].

Mercury has been studied extensively in animal models for its immunotoxic properties, which include both immunosuppression and immunostimulation [14]. Except for those evaluating perinatal exposure [15] or *in vivo* effects of human relevant concentrations [16–19], most animal experiments have only dealt with exposure at higher Hg concentrations. In addition, many reports have addressed the health consequences resulting from low-level exposures such as those occur among dental personnel handling Hg-containing amalgam or among those who have dental amalgam fillings [3,20,21].

The present study was conducted to test the hypothesis that immunomodulation by HgCl<sub>2</sub> in vitro may be affected by changes in cell stimulation pathways. To this end, we adopted two agents of immune cell stimulation, either through monoclonal antibodies (MoAb) or bacterial antigens, to test their effects on the course of immune modulation induced by Hg. We investigated the *in vitro* changes in cell vitality and cytokine secretion profiles of isolated human peripheral blood mononuclear cells (PBMC). In order to avoid potential confounding by non-immunological toxicity of Hg, we intentionally used very low doses of Hg compared with the range used commonly in studies of Hg immunotoxicity.

# **Materials and methods**

## **Preparation of cells**

Blood samples used in this study were obtained as buffy coats of healthy donors from the Blood Bank of Leipzig University Clinic, Germany. The experiments were approved by the local authorities and the informed consent of all participating subjects was obtained. Density gradient centrifugation technique (Ficoll®; Amersham Biosciences, Freiburg, Germany) was applied to separate PBMC that were then collected and washed with phosphate-buffered saline (PBS).

## **Distribution of PBMC subpopulations**

Analysis of the isolated PBMC subpopulations was performed using surface marker staining and flow cytometry. For immunofluorescence staining of cells, the manufacturer's instructions were followed (BD Biosciences, Heidelberg, Germany). A standard set of MoAb against surface antigens was used: Simultest™ CD3/CD8, CD3/CD4, CD3/CD19, CD3/CD16CD56, Simultest™ Leucogate™ (CD45/CD14) and Simultest<sup>™</sup> control  $\gamma$ 1/ $\gamma$ 2a [IgG<sub>1</sub> fluorescein isothiocyanate (FITC)/Ig $G_{2a}$  phycoerythrin (PE)]. The results are given as percentage of positively stained cells in the sample. A gate was set on the lymphocytes in the forward–side scatter plot, which were then analysed to estimate the percentages of T helper (CD3<sup>+</sup>, CD4<sup>+</sup>), T suppressor  $(CD3^+$ ,  $CD8^+$ ), B $(CD3^-$ ,  $CD19^+$ ) and natural killer (NK) cells (CD3– , CD16<sup>+</sup> /CD56<sup>+</sup> ).

## **Cell cultures**

Isolated cells were suspended in HybridoMed DIF 1000 (Biochrom, Berlin, Germany) containing 10 µg/ml gentamycin, 100 mg/ml streptomycin, 100 U/ml penicillin and 10% fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT, USA), incubated at 37 $\mathrm{^{\circ}C}$  with humidified 5%  $\mathrm{CO}_2$  and finally cultured (1 ml/well) in 48-well flat-bottomed microtitre plates (Greiner Bio-one GmbH, Nürtingen, Germany). Cells were activated either by MoAb (anti-CD3: OKT3, mouse IgG1; Ortho Biotech, Bridgewater, NJ, USA; anti-CD28: clone CD28·2, mouse IgG1; Beckman-Coulter, Krefeld, Germany; and anti-CD40: clone B-B20; Trinova Biochem, Gießen, Germany; 100 ng/ml each) or heat-killed *Salmonella enterica* serovar Enteritidis (hk-*S*E: ade– , his– ; Salmovac SE®, Impfstoffwerk Dessau-Tornau, Rosslau, Germany; 1·25 ¥ 105 colony-forming units (CFU)/ml). First, MoAb mixture or hk-*SE* was diluted in culture medium and 450 µl were added to the wells and the plates were preincubated for 1 h for homologous distribution and binding to the plate surface. Finally, cells were added  $(2 \times 10^6 / 500 \,\mu$ l medium) and followed by the application of 50  $\mu$ l serial doses of the heavy metal.

## **Application of mercuric chloride**

Mercuric chloride (Sigma, Steinheim, Germany) was dissolved in deionized water immediately before application. Final concentrations from 15 pg to 50  $\mu$ g/ml were prepared using the same culture medium. Control samples were established where cells received either MoAb or hk-*S*E.

## **Cell vitality response**

Vitality response of Hg-exposed cells to MoAb or hk-*S*E was assessed by MTT assay as described previously [22]. Following harvesting culture supernatant for enzyme-linked immunosorbent assay (ELISA) after 24-h incubation with  $HgCl<sub>2</sub>$ , the remaining cells were suspended in 200  $\mu$ l medium, then  $25 \mu$ l/well MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide, 5 g/l PBS; Sigma] reagent were added and the plates were incubated in the dark for 4 h at 37°C. Then 300 µl/well stop reagent (10% w/v sodium dodecyl sulphate in 50% v/v N,N′-dimethylformamide; SERVA, Heidelberg, Germany) was added and the plates

incubated overnight. The optical density (OD) was evaluated by an automatic plate spectrophotometer (Spectra Image; Tecan, Crailsheim, Germany) at a wavelength of 570 nm and 450 nm reference.

#### **Detection of cytokine release by ELISA**

Following a 24-h incubation period, the release of interleukin (IL)-4, IL-6, IL-10, interferon (IFN)-g and tumour necrosis factor (TNF)- $\alpha$  was determined in cell culture supernatants by commercially available ELISA kits, with lower detection limits of 4 pg/ml (OptEIA™ Kits; BD Biosciences) according to the manufacturer's instructions. Briefly, 384-well microtitre ELISA plates (MaxiSorp, Nunc, Wiesbaden, Germany) were sterile-coated with 50 µl relevant capture antibodies  $(1 \mu g/ml)$  using an automated pipetter (Biomek 2000; Beckmann, Unterschleißheim, Germany) and incubated overnight in a moist chamber at -4°C. The plates were then washed three times with wash buffer using a microtitre-plate wash automate (Tecan, Crailsheim, Germany) and were then blocked with 100 µl/ well assay buffer and incubated at room temperature for 1 h. Following three washing steps, samples and standards were applied and the plates were incubated in a moist chamber for 2 h at room temperature and then washed five times. Detection antibodies  $(0.5 \mu g/ml)$  were applied  $(50 \mu l/well)$  and incubated for 1 h. Following a further seven washes, 3,3′,5,5′ tetramethylbenzidine (TMB)-substrate (50 µl/well; BD Biosciences) was added and the plates were kept in the dark for 20 min before stopping the reaction using 2 M  $H_2SO_4$  (50 µl) well; Merck, Darmstadt, Germany). The OD was measured by automatic plate spectrophotometer (Spectra Image; Tecan) at a wavelength of 450 nm and 620-nm reference.

#### **Intracellular cytokine staining**

To evaluate the functional differentiation of T helper (Th) cells following exposure to Hg, flow-cytometric detection of intracellular cytokines was performed as described previously [22]. Briefly, MoAb-activated human PBMC, isolated as described above, were cultured  $(2 \times 10^6/\text{ml})$  in cell-culture tubes (TPP, Trasadingen, Switzerland) at  $37^{\circ}$ C/5% CO<sub>2</sub> for 24 h in the absence or presence of serial doses of  $HgCl<sub>2</sub>$ . Cells were then washed and received 1·0 ml fresh medium (HybridoMed DIF 1000; Biochrom) containing  $1.0 \mu$ M ionomycin (Calbiochem, Bad Soden, Germany), 2·5 nM phorbol myristate acetate (PMA) and  $2.5 \mu$ M monensin (Sigma). After a 4-h incubation period, cells were fixed with 4% cold paraformaldehyde, permeabilized with 0·1% saponin and stained with FITC-labelled MoAb against CD3 (UCHT1) and PE-labelled MoAb against the cytokines IFN-g (45·15) or IL-4 (4D9; Beckman-Coulter). Mouse IgG1 PE-labelled isotype control was used. Cells were analysed by flow cytometry using Cellquest Software [fluorecence activated cell sorter (FACS)Calibur; BD Biosciences]. For analysis, cytokine-PE labelled cells were then plotted against total T cells. Results were expressed as percentages of the control cells.

## **Quantitative real-time polymerase chain reaction (PCR)**

A similar set of cell cultures were set up as described above to determine changes in cytokine mRNA expression following 24-h exposure to Hg. Total RNA was isolated using the E.Z.N.A.® total RNA Kit (PeqLab, Erlangen, Germany). Transcription into cDNA at 42°C for 1 h was followed using AMV Reverse Transcriptase (Promega, Mannheim, Germany), primer deoxyribonucleoside triphosphate (dNTP) set and oligo-dT  $[5'-pd(T)]_{12-18}-3'$ ; Amersham Biosciences]. The LightCycler PCR and real-time detection system (FastStart DNA Master SYBR Green I reagent Kit; Roche, Mannheim, Germany) were used for detecting IFN- $\gamma$  and IL-4 mRNA. The sequences of the forward and reverse primers used were: (i) the housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH): 5′-G TC AGT GGT GGA CCT GAC CT and 5′-AGG GGA GAT TCA GTG TGG TG; (ii) IL-4: 5′-AGA AGA CTC TGT GCA CCG AGT TGA and 5′-CTC TCA TGA TCG TCT TTA GCC TTT; and (iii) IFN-y: 5'-TTC AGC TCT GCA TCG TTT TG and 5′-TCA GCC ATC ACT TGG ATG AG. The level of GAPDH mRNA was used to normalize the amounts of mRNA in each sample. Cytokine standards (GenExpress, Berlin, Germany) were used for quantification. Results were expressed as percentages of the controls.

#### **Statistical analysis**

Experiments were carried out in triplicate. Data analysis was performed using statistica version 5.1 software (Statsoft, Hamburg, Germany). Variations among cytokine profiles of different donors were tested using a non-parametric analysis of variance (anova), the Kruskal–Wallis test and, in the case of an indication of significant variation, a post-test was performed (Dunn's test). Wilcoxon's rank test for paired samples was used to analyse the differences between controls and Hg-treated cells. The correlation between the different combinations of cytokine release, intracellular cytokine levels and cytokine mRNA expression was analysed using Spearman's rank correlation test. In all tests, significance was determined at *P* < 0·05.

#### **Results**

#### **Phenotypes of PBMC**

For evaluating the immunomodulatory effects of exposure to HgCl<sub>2</sub>, human Ficoll®-isolated PBMC were used. The percentage of lymphocytes varies within a narrow range of  $73.11 \pm 6.56$  of the total PBMC; monocytes were

**Fig. 1.** The vitality response of human peripheral blood mononuclear cells to monoclonal antibodies (MoAb: anti-CD3/-CD28/-CD40) or heat-killed *Salmonella enterica* serovar Enteritidis (hk-*S*E) following exposure to HgCl<sub>2</sub>. Box-plots show the results of MoAb-activated cells obtained from 12 donors (a) and of hk-*S*E-stimulated cells from 10 donors (b) following exposure to the heavy metal. Results are shown as percentages of control cells not exposed to Hg. The asterisks (\*) indicate significant inhibition (*P* < 0·05 in Wilcoxon's rank test).



15 $\cdot$ 37  $\pm$  5 $\cdot$ 95% and granulocytes were 4 $\cdot$ 98  $\pm$  3 $\cdot$ 04%. Of the total lymphocytes, the percentage distribution of the main lymphocyte subpopulations was 70 $\cdot$ 36  $\pm$  6 $\cdot$ 88 for total CD3 $^{\circ}$ T cells,  $41.72 \pm 6.42 \text{ CD}4$ <sup>+</sup> T cells,  $27.25 \pm 8.82$  for CD8<sup>+</sup> T cells,  $9.35 \pm 3.15$  for B cells (CD3<sup>-</sup>,CD19<sup>+</sup>) and  $18.04 \pm 7.18$ for NK (CD3<sup>-</sup>, CD16<sup>+</sup>, CD56<sup>+</sup>) cells.

#### **Cell vitality response**

Cell vitality responses of human PBMC to MoAb or hk-*S*E were significantly decreased at 24 h in cells exposed to  $HgCl<sub>2</sub>$  (Fig. 1). Doses above 15.0 ng/ml exerted significant inhibitory effects on cell vitality, and those above 15·0 mg/ml showed strong cytotoxic effects, where cell vitality decreased by 80–100% in comparison to controls. Mercury doses below 50 ng/ml caused insignificant decrease in cell vitality, and some samples even showed a slight insignificant increase in vitality response at doses up to 15·0 ng/ml.

#### **Cytokine release**

Table 1 shows the cytokine ranges of control samples, where cells were activated either by MoAb or hk-*S*E in the absence of HgCl2. Figures 2 and 3 demonstrate changes of the cytokines produced by MoAb- or hk-*S*E-stimulated human PBMC following 24-h exposure to HgCl<sub>2</sub> in vitro.

Following exposure of MoAb-activated PBMC to HgCl<sub>2</sub>, the release of the proinflammatory cytokines TNF- $\alpha$ (Fig. 2a), IL-6 (Fig. 2b) and the Th1 cytokine IFN- $\gamma$  (Fig. 2c) was reduced. Of 12 samples tested, exceptions were the stimulation of TNF- $\alpha$  and IL-6 release at doses between 1·5 ng/ml and 5·0 mg/ml of three donors, which was remarkable in the case of IL-6 release at doses from  $0.5$  to  $1.5 \mu$ g/ml; variations between samples were insignificant (*P* > 0·05, Kruskal–Wallis test). In the case of IFN-g, only two samples showed an increase of IFN- $\gamma$  at doses from 15 pg/ml to 1·5 mg/ml and 5–500 ng/ml; data not shown separately. The levels of IL-4 and IL-10 increased significantly (*P* < 0·05 at Wilcoxon's rank test) at lower doses from 50 pg/ml to 15 and from 150 pg/ml to 50 ng/ml, respectively (Fig. 2d–e). Because a balance between both T helper cell types Th1 and Th2 is hypothesized to exist, the ratios of %IFN- $\gamma$ /%IL-4 and %IFN- $\gamma$ /%IL-10 were estimated (Fig. 2f–g) to assess any modulation of this balance. At all Hg doses from 50 pg/ml to 5 µg/ml significantly reduced ratios ( $P < 0.05$  at Wilcoxon's rank test) were found, indicating Th2-biased immune responses.

Figure 3 represents changes in cytokine profiles of hk-*S*Estimulated cells exposed to HgCl<sub>2</sub> for 24 h. Compared to the

**Table 1.** Ranges of the different cytokines (pg/ml) produced by monoclonal antibodies [monoclonal antibodies (MoAb): anti-CD3/-CD28/CD40] or heat-killed *Salmonella enterica* serovar Enteritidis (hk-*S*E)-activated human peripheral blood mononuclear cells (PBMC) cultured for 24 h. These data were used as controls to assess the effects of exposure to HgCl<sub>2</sub> on cytokine production *in vitro*.



a The median, the 10th and the 90th percentiles of each cytokine are represented as measured by enzyme-linked immunosorbent assay. IL: interleukin; IFN: interferon; TNF: tumour necrosis factor.



Fig. 2. The effect of HgCl<sub>2</sub> on the *in vitro* monoclonal antibody (MoAb)-activated release of tumour necrosis factor (TNF)- $\alpha$  (a), interleukin (IL)-6 (b), interferon (IFN)- $\gamma$  (c), IL-4 (d) and IL-10 (e) by human peripheral blood mononuclear cells (PBMC). Box-plots show data of 12 samples, each with three replicates. T helper 1 (Th1)/Th2 ratios were evaluated from %IFN- $\gamma$ /%IL-4 (f) and %IFN- $\gamma$ /%IL-10 (g). Symbols above each plots show whether, at each dose, cytokine release was significantly stimulated (#) or suppressed (\*) compared with the controls (*P* < 0·05 in Wilcoxon's rank test).



Fig. 3. The effect of HgCl<sub>2</sub> on the *in vitro* heat-killed *Salmonella enterica* serovar Enteritidis (hk-*SE*)-stimulated release of tumour necrosis factor (TNF)- $\alpha$  (a), interleukin (IL)-6 (b), interferon (IFN)- $\gamma$  (c) and IL-10 (d) by human peripheral blood mononuclear cells. Data of 10 samples, each with three replicates, are demonstrated. T helper 1 (Th1)/Th2 ratios were evaluated from %IFN- $\gamma$ /%IL-10 ratio (e). Symbols above each plot show whether, at each dose, cytokine release was significantly stimulated (#) or suppressed (\*) compared with the controls (*P* < 0·05 in Wilcoxon's rank test).

Fig. 4. The effect of HgCl<sub>2</sub> on the *in vitro* MoAb-induced production of interferon (IFN)- $\gamma$  (a) and interleukin (IL)-4 (b) by human peripheral blood mononuclear cells as evaluated by intracellular cytokine staining. Results of five donors are shown as percentages of intracellular cytokine-phycoerythrin labelled to the total fluorescein isothiocyanate-labelled CD3<sup>+</sup> T cells. T helper 1 (Th1)/Th2 ratios (c) were estimated from %IFN- $\gamma$ /%IL-4.

 $\blacktriangleright$ 

case of MoAb-activated cells, the inhibition of TNF- $\alpha$  and IL-6 were more pronounced at Hg doses from 50 pg to 150 ng/ml and from 150 pg to 150 ng/ml for both cytokines, respectively. The release of IFN- $\gamma$  (Fig. 3c), however, was stimulated significantly at doses from 50 pg up to  $0.5 \text{ µg/ml}$ , and then decreased steadily when vitality drops below 80% (Fig. 1b). The release of IL-4 was undetectable, and IL-10 release showed an insignificant variation in the 10 samples tested (Fig. 3d). The ratios of %IFN-g/%IL-10 indicated deviation of the immune response toward Th1 type (Fig. 3e) due to the relative increase of IFN-g *versus* IL-10 production.

#### **Intracellular cytokines**

Intracellular cytokine staining of MoAb-activated cells exposed to  $HgCl<sub>2</sub>$  for 24 h revealed changes in the proportion of IFN-g- as well as IL-4-producing cells of the total viable T cells in comparison to control cells (Fig. 4). With few exceptions, a decrease in the number of IFN-y-producing cells was found as a result of exposure to  $HgCl<sub>2</sub>$  (Fig. 4a).

On the other hand, the number of IL-4-producing T cells increased in all tested samples at doses from 15 pg to  $1.5 \mu g$ / ml, and then decreased with the increase in cytotoxicity (Fig. 4b). This led to a decrease in the %IFN-g/%IL-4 ratio at all tested doses up to  $1.5 \mu g/ml$ , which indicates favouring IL-4-producing cells, namely Th2 cells, in comparison to IFN- $\gamma$ -producing Th1 cells (Fig. 4c).

#### **Cytokine mRNA expression**

Figure 5 represents modulation of the mRNA expression of IL-4 and IFN-g by MoAb-activated human PBMC following 24-h exposure to  $HgCl<sub>2</sub>$ . Although both show a declining tendency with the increase of Hg dose, it is clear that expression of the IL-4 mRNA was stimulated comparable to IFN-g mRNA (Fig. 5a). This is represented clearly by estimating the Th1/Th2 ratios (Fig. 5b). With the exception of only one of five tested samples at 15 pg/ml and  $1.5 \mu$ g/ml, these ratios indicate that all tested doses deviate the immune response toward Th2 type, and refer therefore to the modulation of the immune response by Hg at the early stages of cytokine synthesis.

## **Discussion**

Heavy metal pollution has attained high visibility in the public arena and increasingly become a major scientific





**Fig. 5.** Cytokine mRNA expression, measured by reverse transcription–polymerase chain reaction, of monoclonal antibody (MoAb)-stimulated human peripheral blood mononuclear cells (PBMC) exposed for 24 h to HgCl<sub>2</sub>. Results of five donors are shown as percentages of controls for both IL-4 and IFN- $\gamma$  (a). The ratios of %IFN- $\gamma$ /%IL-4 were estimated to assess modulation of the Th1/Th2 balance (b).

concern. Most of the early studies addressed the effects of relatively higher doses that are not relevant to most populations. In addition, only recently has the threshold of Hg toxicity been considered with regard to the immune system as a direct target of mercurial exposure [5]. Nowadays, exposure of humans to low levels of Hg through its use in industry and as a component of amalgam fillings warrants further studies targeted at investigating the possible effects of these levels and their relevance to diseases. Because of the great sensitivity of the immune system, determining the optimal exposure doses for immunological testing and attempting to extrapolate between different endpoints in risk assessment is of crucial importance [5]. Among others, disturbances in cytokine production, an important agent in the aetiology of many diseases [23], may be the most relevant indicator to address the effect of xenobiotic agents [24]. Therefore, through applying two model systems of immune cell stimulation and three different methods to detect changes in cytokine profiles, the present study was undertaken to evaluate modulation of cytokine production following exposure to HgCl<sub>2</sub>. We used a wide range of exposure doses, from toxic levels as indicated by cell cytotoxicity and downwards to very low levels, thought to be ineffective.

Based on their cytokine secretion patterns and effector functions, naive CD4<sup>+</sup> T helper cells (Th0) have been shown to differentiate into at least two subsets, Th1 and Th2, both in mice [25–27] and in humans [28,29]. These cells secrete different but overlapping sets of cytokines. Th0 cells secrete cytokines including IL-2, IL-4 and IFN-g. Whereas Th1 cells produce IL-2, IFN- $\gamma$ , TNF- $\beta$  and low levels of IL-10, Th2 cells produce IL-4, IL-5, IL-9, IL-10, IL-13 [25,26,30] and IL-6 [31]. Differentiation of Th0 towards Th1 or Th2 is believed to be a consequence of several cellular influences, such as the cytokine milieu. Th0 cells differentiate into Th1 cells when stimulated in the presence of IL-12 and into Th2 cells when stimulated in the presence of IL-4 [32]. Moreover, there is cross-regulation between Th1 and Th2 in a variety of ways. For example, secretion of IL-4 by Th2 cells blocks differentiation of Th0 into Th1 cells. Production of IL-4, IL-13 and IL-10 by Th2 cells may suppress Th1 cells and many IFN-y-induced macrophage functions. Conversely, Th1 cells secrete IFN-g, which inhibits the proliferation of Th2 cells [25,32,33]. The dominance of one of these subsets results in either a predominantly cellular (Th1-mediated) or antibody (Th2-mediated) response [4]. For instance, altering the Th1/Th2 balance may lead to the onset and/or exacerbation of autoimmune disorders [34–36], and may even help find therapeutic possibilities [37]. We assessed the modulation of the Th $1$ /Th $2$  balance due to exposure to HgCl<sub>2</sub> using the %IFN-g/%IL-4 ratios. In accordance with previous reports, IFN- $\gamma$  levels in all samples were higher than IL-4 levels. Therefore, according to Lawrence *et al*. [36], estimating %IFN- $\gamma$ /%IL-4 ratios may be more relevant than the actual number of IL-4- or IFN-y-producing cells or the amount of the produced cytokines.

Our results provide evidence that applying different pathways of immune stimulation determines the immunomodulatory effects elicited by exposure to HgCl<sub>2</sub> in vitro. While high Hg doses are highly toxic, as indicated by significant decrease in cell vitality, exposure to lower and moderate doses exerts immunomodulatory effects resulting in inclination of the immune response towards type 2 in MoAbactivated cells due to induction of IL-4 and IL-10 release. Production of the Th1 cytokine IFN- $\gamma$  as well as the proinflammatory cytokines TNF- $\alpha$  and IL-6 was reduced. These immunomodulatory effects could be confirmed by measuring the intracellular cytokines of T cells and also at the mRNA level, indicating the preference of Th2 response in MoAb-activated PBMC. However, some samples showed insignificantly different effects following exposure to Hg *in vitro*. Unfortunately, our figures are limited by the lack of background of the subjects used, which could help understanding of these differences in individual susceptibility that could be linked to genetic factors [38].

As mentioned above, we evaluated modulation of cytokine profiles following exposure to HgCl<sub>2</sub> in vitro using ELISA





\*\*\**P* < 0.001; \*\**P* < 0.05.

to detect cytokine release, flow cytometric analysis to detect intracellular cytokine levels and reverse transcription (RT)– PCR to assess cytokine mRNA expression. We carried out a correlation analysis to test the relevance of these methods (Table 2). A positive correlation was found in all cases of IFN-g, indicating the relevance of these methods to assess the cytokine profile. In the case of IL-4, on the other hand, with the exception of two cases that showed strong positive correlation, there was no correlation between these different methods. This variation may be attributed to the instant uptake of IL-4 by cells following its release. Use of anti-IL-4 receptor antibodies would have been more relevant to assess the actual levels of IL-4 release. However, the suppression of IFN- $\gamma$  production which was accompanied by induction of IL-4 release indicates that the polarization of cytokine production begins early at the transcriptional stages, which corresponds with previous studies [39–41], indicating a Th2 polarized immune response in Hg-exposed cells in the case of MoAb stimulation.

Results of hk-*S*E-activated cells show that exposure to Hg promoted the type 1-polarized responses induced by bacterial antigens, as indicated by an increase in IFN- $\gamma$  production. However, at identical concentrations, both TNF- $\alpha$ and IL-6 production were reduced significantly, implying a selective suppression of macrophage/monocyte system by Hg, which is consistent with previous studies [42]. Because of the induction of some cytokines at intermediate Hg doses, the overall behaviour may be the result of an overlap of toxic effects starting at low doses, and cytokine-induced cell proliferation or induction of cytokine production at moderate doses. Another reason for this biphasic pattern of cytokine production may be due to differences in cell sensitivity [43,44] and/or individual susceptibility. The increase of the Th1/Th2 ratio in the presence of *Salmonella* antigens, which is comparable to lipopolysaccharide (LPS), has recently shown its important clinical implications [45]. Moreover, we extend the earlier studies on Hg immunotoxicity by demonstrating that even low doses of Hg, that cannot affect cell vitality of human immune cells

*in vitro*, can disturb cytokine production as reported previously [24].

Although many studies have been performed on cytotoxic effects of metals on human immunocompetent cells, some inconsistencies have evolved, especially regarding the effects of low-dose exposure in humans. Despite the welldocumented effects elicited by high and moderate doses, some studies demonstrated only negligible, if any, influences of low-level exposure to Hg [46–52]. With regard to cytotoxic effects of Hg, our results are consistent with previous studies [53–56]. The immunotoxicity of Hg is complex involving, on one hand, immunosuppression, but on the other hand immunopotentiation. For a long time, the effect of mercurials on the immune system was synonymous with immunosuppression [6]. Exposure to Hg increased animal susceptibility to infectious agents possibly by inhibiting cellular [57] and/or humoral [58,59] responses. Human studies endorsed this view where a decrease in T cell proliferation [54] or B cell counts resulted following exposure to Hg [60]. On the other hand, *in vitro* exposure to inorganic Hg was found to induce human lymphocyte activity [61] and humoral immunity in Hg-exposed workers [62], and to increase splenic T and B cells in genetically Hg-susceptible mice strains [63]. There are many explanations for these discrepancies [3,5,44], including genetic and cellular differences as well as an array of experimental factors that may profoundly influence the outcome of the *in vitro* studies.

The immunomodulatory effects of Hg found in the present study are consistent with previous reports. The trend of inclination towards a type 2 response is similar to that described in several *in vitro* and *in vivo* studies [37,40,64–70], as well as in workers occupationally exposed to Hg [71]. For instance, *in vitro* IL-4 production by a Th2 clone was increased significantly by the addition of  $27·2-1360$  ng/ml HgCl<sub>2</sub>, whereas IFN-g production by a Th1 clone was decreased [68]. Similarly, in human basophils [72], whereas  $0.272-272 \mu$ g/ml HgCl<sub>2</sub> promoted Th2 cytokine profiles as indicated by high levels of IL-4 and IL-13, higher doses of  $2.72 \mu g$ / ml-272 ng/ml strikingly reduced cell viability; however,

toxicity varied depending on cell density and incubation time. Using two murine T cell hybridomas (SM1·27·9 and 1H11·3), Badou *et al.* [64] found that exposure to HgCl<sub>2</sub> induced both IL-4 mRNA expression as well as cytokine release. The latter authors proposed a mechanistic pathway that HgCl2 induces a protein kinase C-dependent Ca<sup>2+</sup> influx through L-type channels leading to IL-4 gene induction in cells that are engaged in IL-4 production, thereby initiating differentiation of Th2 cells. The predominance of Th2-associated IL-4 is also a well-known feature of HgCl<sub>2</sub>-treated genetically susceptible rats [73,74] and mouse [67,68,75]. When BALB/c mice were exposed subcutaneously to HgCl<sub>2</sub> ex vivo IL-4 production by anti-CD3-stimulated splenic T cells was enhanced, but IFN-g production was inhibited [68]. Additionally, the plasma IL-4 and IgE levels of Hg-exposed mice were increased and IFN-g levels were lowered significantly in the absence of exogenous antigen.

It is important to consider the combined weight of evidence of Hg accumulation, bioavailability, metabolism and mode of action with regard to threshold of toxicity and potential immunomodulation [5]. This will help to develop risk estimations by comparing Hg concentrations in specific tissues and endpoints that are likely to result in adverse effects. In this study, we applied a wide range of Hg doses. In terms of Hg levels in human blood, we used biologically relevant doses lower than those found in people who live in contaminated areas  $(0.02 \mu g/ml$  [76]), obtained through occupational exposure (2·0–98·0 ng/ml [77]) or in people with amalgam restorations  $(0.1-2.55 \text{ ng/ml } [78,79])$  and up to toxic levels. Despite the existence of constraints in the extrapolation of *in vitro* to *in vivo* situation, for example due to many Hg neutralizing factors in the tissues, our results reveal immunomodulatory effects at doses as low as 50 pg/ml which are lower than the current acceptable threshold blood Hg level of  $4.0-5.0 \mu g/l$  [2,12,13]. These results are consistent with previous reports that indicated cytotoxic effects of comparable doses [80] and should be taken into account in the preliminary assessment of the risks to human.

Due to its effects on cytokine and immunoglobulin production, Hg has been implicated in the induction of allergic [72,81] and autoimmune [10,34,82] diseases. In allergies, it is known that reactions of type 1 response, evoked normally by IL-2, TNF- $\alpha$  and IFN- $\gamma$ , are deficient and a type 2 response, driven by IL-4, IL-13, IL-5 and IL-10 [36,83], predominates and is responsible for immunoglobulin classswitching from IgM to IgE [36]. Thus, in susceptible mouse strains, serum IgE increased dose-dependently and reached a maximum after 1–2·5 weeks following exposure to Hg [84]. The immunomodulative potency of Hg, as indicated here and by previous studies, confirms the implication of the metal in the induction of allergic and autoimmune diseases. Moreover, our results imply that the pathways of activating immune cells should be considered in such *in vitro* systems aiming at evaluation of immunomodulation by xenobiotic agents such as Hg, especially at low exposure levels.

In conclusion, short-term exposure to low and moderate doses of Hg suppresses the MoAb-stimulated production of IFN- $\gamma$ , TNF- $\alpha$  and IL-6, and alternatively induces type 2 responses, as evidenced by increases in IL-4 and IL-10 levels. The two later cytokines induce and maintain a type 2 immune response, which raises the possibility of Hg-induced allergic diseases, and the development of Th2 dominant autoimmunity. Contrarily, Hg at concentrations from 50 pg/ml to 500 ng/ml can promote the type 1 biased immune response induced by bacterial antigens of *S. enterica*. At these doses the macrophage activity, however, is suppressed, implying that Hg exerts distinct effects on different immune cell types. Further studies may be conducted to identify specific target cells of Hg immunomodulatory effects. In order to extrapolate between different end-points of risk assessment, current *in vivo* studies are being undertaken to delineate the biological relevance of these findings and to determine whether low-level exposure to Hg might be problematic in terms of risk for immunological disorders and susceptibility to infectious agents. Overall, this study reflects the importance of considering immune stimulation regimes while investigating the immune modulation by xenobiotic agents such as heavy metals *in vitro*.

## **Acknowledgements**

We acknowledge the valuable technical assistance of Ms Sylke Drubig (Department of Environmental Immunology, UFZ) and Ms Heike Knaack (IKIT, University of Leipzig). We are also grateful to Dr Sonya Faber (Fraunhofer Institute for Cell Therapy and Immunology) for reviewing the manuscript. This work was funded by a grant from the Interdisziplinäres Zentrum für Klinische Forschung Leipzig (IZKF) of the Medical Faculty, University of Leipzig, Germany (project Z10).

#### **References**

- 1 Clarkson TW. The three modern faces of mercury. Environ Health Perspect 2002; **110** (Suppl. 1):11–23.
- 2 Clarkson TW, Magos L, Myers GJ. The toxicology of mercury -current exposures and clinical manifestations. N Engl J Med 2003; **349**:1731–7.
- 3 Enestrom S, Hultman P. Does amalgam affect the immune system? A controversial issue. Int Arch Allergy Immunol 1995; **106**:180– 203.
- 4 Tchounwou PB, Ayensu WK, Ninashvili N, Sutton D. Environmental exposure to mercury and its toxicopathologic implications for public health. Environ Toxicol 2003; **18**:149–75.
- 5 Sweet LI, Zelikoff JT. Toxicology and immunotoxicology of mercury: a comparative review in fish and humans. J Toxicol Environ Health B Crit Rev 2001; **4**:161–205.
- 6 Havarinasab S, Hultman P. Organic mercury compounds and autoimmunity. Autoimmun Rev 2005; **4**:270–5.
- 7 Via CS, Nguyen P, Niculescu F, Papadimitriou J, Hoover D, Silbergeld EK. Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. Environ Health Perspect 2003; **111**:1273–7.
- 8 Silbergeld EK, Silva IA, Nyland JF. Mercury and autoimmunity: implications for occupational and environmental health. Toxicol Appl Pharmacol 2005; **207**:282–92.
- 9 Monnet-Tschudi F, Zurich MG, Boschat C, Corbaz A, Honegger P. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. Rev Environ Health 2006; **21**:105–17.
- 10 Hultman P, Taylor A, Yang JM, Pollard KM. The effect of xenobiotic exposure on spontaneous autoimmunity in  $(SWR \times SJL)$  F1 hybrid mice. J Toxicol Environ Health A 2006; **69**:505–23.
- 11 World Health Organization (WHO). *Evaluation of Certain Food Additives and Contaminants*. Twenty-second report of the joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series. Geneva: WHO, 1978:1–39.
- 12 US Environmental Protection Agency (EPA). Mercury Study Report to Congress, Office of Air Quality Planning & Standards and Office of Research and Development, Volume IV: an Assessment of Exposure to Mercury in the United States. EPA-452/R-97- 006, 1997.<http://www.epa.gov/ttn/oarpg/t3/reports/volume4.pdf>
- 13 Ip P, Wong V, Ho M, Lee J, Wong W. Environmental mercury exposure in children: South China's experience. Pediatr Int 2004; **46**:715–21.
- 14 Clarkson TW. The toxicology of mercury. Crit Rev Clin Lab Sci 1997; **34**:369–403.
- 15 Mitchell RJ, Osborne PB, Haubenreich JE. Dental amalgam restorations: daily mercury dose and biocompatibility. J Long Term Effect Med 2005; **15**:709–21.
- 16 Hultman P, Enestrom S. Dose–response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicol Appl Pharmacol 1992; **113**:199–208.
- 17 Yoshida M, Watanabe C, Satoh M *et al.* Susceptibility of metallothionein-null mice to the behavioral alterations caused by exposure to mercury vapor at human-relevant concentration. Toxicol Sci 2004; **80**:69–73.
- 18 Warfvinge K, Hansson H, Hultman P. Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose–response studies. Toxicol Appl Pharmacol 1995; **132**:299– 309.
- 19 Havarinasab S, Lambertsson L, Qvarnstrom J, Hultman P. Dose– response study of thimerosal-induced murine systemic autoimmunity. Toxicol Appl Pharmacol 2004; **194**:169–79.
- 20 Echeverria D, Woods JS, Heyer NJ *et al.* The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans. Neurotoxicol Teratol 2006; **28**:39–48.
- 21 Woods JS, Echeverria D, Heyer NJ, Simmonds PL, Wilkerson J, Farin FM. The association between genetic polymorphisms of coproporphyrinogen oxidase and an atypical porphyrinogenic response to mercury exposure in humans. Toxicol Appl Pharmacol 2005; **206**:113–20.
- 22 Hemdan NYA, Emmrich F, Adham K *et al.* Dose-dependent modulation of the *in vitro* cytokine production of human immune competent cells by lead salts. Toxicol Sci 2005; **86**:75–83.
- 23 Haggqvist B, Hultman P. Murine metal-induced systemic autoimmunity: baseline and stimulated cytokine mRNA expression in genetically susceptible and resistant strains. Clin Exp Immunol 2001; **126**:157–64.
- 24 Shen X, Lee K, Konig R. Effects of heavy metal ions on resting and antigen-activated CD4(+) T cells. Toxicology 2001; **169**:67– 80.
- 25 Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; **7**:145–73.
- 26 Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; **12**:A49–A53.
- 27 Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; **17**:138–46.
- 28 Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; **12**:256–7.
- 29 Umetsu DT, Jabara HH, DeKruyff RH, Abbas AK, Abrams JS, Geha RS. Functional heterogeneity among human inducer T cell clones. J Immunol 1988; **140**:4211–6.
- 30 Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987; **166**:1229–44.
- 31 Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; **164**:4878–82.
- 32 Seder RA, Paul WE, Davis MM, Fazekas DS. The presence of interleukin 4 during *in vitro* priming determines the lymphokineproducing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; **176**:1091–8.
- 33 Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; **383**:787–93.
- 34 Hultman P, Johansson U, Dagnaes-Hansen F. Murine mercuryinduced autoimmunity: the role of T-helper cells. J Autoimmun 1995; **8**:809–23.
- 35 Lafaille JJ. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 1998; **9**:139–51.
- 36 Lawrence DA, McCabe MJ Jr. Immunomodulation by metals. Int Immunopharmacol 2002; **2**:293–302.
- 37 Haggqvist B, Hultman P. Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response. Clin Exp Immunol 2003; **134**:202–9.
- 38 Gleichmann E, Kimber I, Purchase IF. Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion. Arch Toxicol 1989; **63**:257–73.
- 39 Haggqvist B, Hultman P. Interleukin-10 in murine metal-induced systemic autoimmunity. Clin Exp Immunol 2005; **141**:422–31.
- 40 Hansson M, Djerbi M, Rabbani H *et al.* Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice. Immunology 2005; **114**:428–37.
- 41 Havarinasab S, Haggqvist B, Bjorn E, Pollard KM, Hultman P. Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol Appl Pharmacol 2005; **204**:109–21.
- 42 Vimercati L, Santarelli L, Pesola G *et al.* Monocyte–macrophage system and polymorphonuclear leukocytes in workers exposed to low levels of metallic mercury. Sci Total Environ 2001; **270**:157–63.
- 43 Shenker BJ, Berthold P, Decker S *et al.* Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. II. Alterations in cell viability. Immunopharmacol Immunotoxicol 1992; **14**:555–77.
- 44 Waalkes MP, Fox DA, States JC, Patierno SR, McCabe MJ Jr. Metals and disorders of cell accumulation: modulation of apoptosis and cell proliferation. Toxicol Sci 2000; **56**:255–61.
- 45 Abedi-Valugerdi M, Nilsson C, Zargari A, Gharibdoost F, Depierre JW, Hassan M. Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice. Clin Exp Immunol 2005; **141**:238–47.
- 46 Hansteen IL, Ellingsen DG, Clausen KO, Kjuus H. Chromosome aberrations in chloralkali workers previously exposed to mercury vapor. Scand J Work Environ Health 1993; **19**:375–81.
- 47 Mabille V, Roels H, Jacquet P, Leonard A, Lauwerys R. Cytogenetic examination of leucocytes of workers exposed to mercury vapour. Int Arch Occup Environ Health 1984; **53**:257–60.
- 48 Loftenius A, Sandborgh-Englund G, Ekstrand J. Acute exposure to mercury from amalgam: no short-time effect on the peripheral blood lymphocytes in healthy individuals. J Toxicol Environ Health A 1998; **54**:547–60.
- 49 Sandborgh-Englund G, af Geijersstam E, Loftenius A. Rapid communication: acute exposure to mercury from dental amalgam does not affect the levels of C-reactive protein or interleukin-6 in peripheral blood. J Toxicol Environ Health A 2003; **66**:495–9.
- 50 Issa Y, Watts DC, Duxbury AJ, Brunton PA, Watson MB, Waters CM. Mercuric chloride: toxicity and apoptosis in a human oligodendroglial cell line MO3.13. Biomaterials 2003; **24**:981–7.
- 51 Luglie PF, Campus G, Chessa G *et al.* Effect of amalgam fillings on the mercury concentration in human amniotic fluid. Arch Gynecol Obstet 2005; **271**:138–42.
- 52 Kingman A, Albers JW, Arezzo JC, Garabrant DH, Michalek JE. Amalgam exposure and neurological function. Neurotoxicology 2005; **26**:241–55.
- 53 Yamada H, Koizumi S. Metallothionein induction in human peripheral blood lymphocytes by heavy metals. Chem Biol Interact 1991; **78**:347–54.
- 54 Shenker BJ, Rooney C, Vitale L, Shapiro IM. Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. I. Suppression of T-cell activation. Immunopharmacol Immunotoxicol 1992; **14**:539–53.
- 55 Shenker BJ, Berthold P, Rooney C, Vitale L, DeBolt K, Shapiro IM. Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. III. Alterations in B-cell function and viability. Immunopharmacol Immunotoxicol 1993; **15**:87–112.
- 56 Steffensen IL, Mesna OJ, Andruchow E, Namork E, Hylland K, Andersen RA. Cytotoxicity and accumulation of Hg, Ag, Cd, Cu, Pb and Zn in human peripheral T and B lymphocytes and monocytes *in vitro*. Gen Pharmacol 1994; **25**:1621–33.
- 57 Lawrence DA. *In vivo* and *in vitro* effects of lead on humoral and cell-mediated immunity. Infect Immun 1981; **31**:136–43.
- 58 Koller LD, Exon JH, Brauner JA. Methylmercury: decreased antibody formation in mice. Proc Soc Exp Biol Med 1977; **155**:602–4.
- 59 Lawrence DA. Heavy metal modulation of lymphocyte activities. 1. *In vitro* effects of heavy metals on primary humoral immune responses. Toxicol Appl Pharmacol 1981; **57**:439–51.
- 60 Lawrence DAS, Mudzinski U, Rudofsky G, Warner. Mechanisms of metal-induced immunotoxicity. In: Berlin A, Dean J, Draper MH, Smith EMB, Spreafico F, eds. Immunotoxicology. Dordrecht: Martinus-Nigoff, 1987:293–307.
- 61 Loftenius A, Ekstrand J, Moller E. HgCl(2)-induced human lymphocyte activation *in vitro*: a superantigenic mechanism? Int Arch Allergy Immunol 1999; **120**:63–70.
- 62 Bencko V, Wagner V, Wagnerova M, Ondrejcak V. Immunological profiles in workers occupationally exposed to inorganic mercury. J Hyg Epidemiol Microbiol Immunol 1990; **34**:9–15.
- 63 Johansson U, Hansson-Georgiadis H, Hultman P. The genotype determines the B cell response in mercury-treated mice. Int Arch Allergy Immunol 1998; **116**:295–305.
- 64 Badou A, Savignac M, Moreau M *et al.* HgCl2-induced interleukin-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through 1-type calcium channels. J Biol Chem 1997; **272**:32411–8.
- 65 Bagenstose LM, Salgame P, Monestier M. Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Immunologic Res 1999; **20**:67–78.
- 66 Goldman M, Druet P, Gleichmann E. TH2 cells in systemic autoimmunity. insights from allogeneic diseases and chemicallyinduced autoimmunity. Immunol Today 1991; **12**:223–7.
- 67 Ochel M, Vohr HW, Pfeiffer C, Gleichmann E. IL-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J Immunol 1991; **146**:3006– 11.
- 68 Heo Y, Parsons PJ, Lawrence DA. Lead differentially modifies cytokine production *in vitro* and *in vivo*. Toxicol Appl Pharmacol 1996; **138**:149–57.
- 69 Heo Y, Lee WT, Lawrence DA. *In vivo* the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities. Cell Immunol 1997; **179**:185–95.
- 70 Fournie GJ, Saoudi A, Druet P, Pelletier L. Th2-type immunopathological manifestations induced by mercury chloride or gold salts in the rat: signal transduction pathways, cellular mechanisms and genetic control. Autoimmun Rev 2002; **1**:205–12.
- 71 Soleo L, Vacca A, Vimercati L *et al.* Minimal immunological effects on workers with prolonged low exposure to inorganic mercury. Occup Environ Med 1997; **54**:437–42.
- 72 Strenzke N, Grabbe J, Plath KE, Rohwer J, Wolff HH, Gibbs BF. Mercuric chloride enhances immunoglobulin E-dependent mediator release from human basophils. Toxicol Appl Pharmacol 2001; **174**:257–63.
- 73 Gillespie KM, Qasim FJ, Tibbatts LM, Thiru S, Oliveira DB, Mathieson PW. Interleukin-4 gene expression in mercury-induced autoimmunity. Scand J Immunol 1995; **41**:268–72.
- 74 Prigent P, Saoudi A, Pannetier C *et al.* Mercuric chloride, a chemical responsible for T helper cell (Th) 2-mediated autoimmunity in brown Norway rats, directly triggers T cells to produce interleukin-4. J Clin Invest 1995; **96**:1484–9.
- 75 Johansson U, Sander B, Hultman P. Effects of the murine genotype on T cell activation and cytokine production in murine mercuryinduced autoimmunity. J Autoimmun 1997; **10**:347–55.
- 76 Gochfeld M. Cases of mercury exposure, bioavailability, and absorption. Ecotoxicol Environ Saf 2003; **56**:174–9.
- 77 Counter SA, Buchanan LH, Ortega F, Laurell G. Elevated blood mercury and neuro-otological observations in children of the Ecuadorian gold mines. J Toxicol Environ Health A 2002; **65**:149– 63.
- 78 Kingman A, Albertini T, Brown LJ. Mercury concentrations in urine and whole blood associated with amalgam exposure in a US military population. J Dent Res 1998; **77**:461–71.
- 79 Ganss C, Gottwald B, Traenckner I *et al.* Relation between mercury concentrations in saliva, blood, and urine in subjects with amalgam restorations. Clin Oral Invest 2000; **4**:206–11.
- 80 Silva-Pereira LC, Cardoso PC, Leite DS *et al.* Cytotoxicity and genotoxicity of low doses of mercury chloride and methylmercury chloride on human lymphocytes in vitro. Braz J Med Res 2005; **38**:901–7.
- 81 Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis 2004; **50**:349–53.
- 82 Röger J, Zillikens D, Hartmann A, Burg G. Systemic autoimmune disease in a patient with long-standing exposure to mercury. Eur J Dermatol 1992; **2**:168–70.
- 83 Dubey C, Bellon B, Druet P. TH1 and TH2 dependent cytokines in experimental autoimmunity and immune reactions induced by chemicals. Eur Cytokine Netw 1991; **2**:147–52.
- 84 Nielsen JB, Hultman P. Mercury-induced autoimmunity in mice. Environ Health Perspect 2002; **110** (Suppl. 5):877–81.